+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions

Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions

Antiviral Therapy 15(3): 321-331

This study aimed to examine how CC chemokine receptor 5 (CCR5) inhibitors (aplaviroc [APL], TAK779 and maraviroc [MVC]) interact with CCR5 and affect its dynamics and physiological CC-chemokine-CCR5 interactions. A yellow fluorescent protein (YFP)-tagged CCR5-expressing U373-MAGI cell line was generated and a stable CCR5-expressing clonal population, (YFP)CCR5-UM16, was prepared. (YFP)CCR5-UM16 cells were exposed to RANTES, macrophage inflammatory protein (MIP)-1alpha or MIP-1beta (all 100 ng/ml) with or without CCR5 inhibitors and (YFP)CCR5 internalization was visualized with real-time by laser scanning confocal microscopy. The mobility of (YFP)CCR5 was also examined in the presence of CCR5 inhibitors with fluorescence recovery after photobleaching (FRAP) imaging. Following the addition of each CC chemokine, intracellular fluorescence intensity increased whereas membranous fluorescence decreased, signifying (YFP)CCR5 internalization. All three CCR5 inhibitors failed to induce (YFP)CCR5 internalization. All three CCR5 inhibitors blocked the CC-chemokine-induced internalization at a high concentration of 1 microM; however, the ratio of APL concentration that blocked RANTES-induced internalization by 50% over APL concentration that blocked HIV type-1 (HIV-1) replication by 50% was 16.4, indicating that APL permits CC-chemokine-induced internalization to a much greater extent compared with TAK779 and MVC, having ratios of 1.1 and 0.9, respectively. The examination of (YFP)CCR5 mobility with FRAP imaging revealed that (YFP)CCR5 continuously underwent rapid redistribution, which none of the three inhibitors blocked. The finding that APL moderately blocked the RANTES-triggered (YFP)CCR5 internalization despite the highly potent anti-HIV-1 activity of APL strongly suggests that development of CCR5 inhibitors, which do not overly inhibit physiological CC-chemokine-CCR5 interactions, is practically feasible.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052847659

Download citation: RISBibTeXText

PMID: 20516552

DOI: 10.3851/imp1529

Related references

Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. International Journal of Immunogenetics 32(2): 99-106, 2005

A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. Aids Research and Human Retroviruses 26(6): 653-661, 2010

C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. Journal of General Virology 91(Pt 12): 2965-2973, 2010

Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology 402(1): 135-148, 2010

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Archives of Dermatological Research 299(7): 305-313, 2007

Biological consequences of chemokine receptor polarization on TH1 and TH2 cells from individuals wildtype for CCR5 or homozygous for the DELTA32 CCR5 allele. Blood 92(10 SUPPL 1 PART 1-2): 21A, Nov 15, 1998

Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. Journal of Biological Chemistry 274(13): 8875-8885, 1999

Differential effects of CC-chemokines on the phosphorylation of CC chemokine receptor CCR5 and identification of phosphorylation sites on the CCR5 carboxyterminus. European Journal of Cell Biology 78(SUPPL 49): 75, 1999

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. Journal of Virology 78(16): 8654-8662, 2004

Relationship Between the Chemokine Receptor Ccr5 and Microglia in Neurological Disorders: Consequences of Targeting Ccr5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy. Cns & Neurological Disorders - Drug Targets 12(6): 815-829, 2013

Relationship between the chemokine receptor CCR5 and microglia in neurological disorders: consequences of targeting CCR5 on neuroinflammation, neuronal death and regeneration in a model of epilepsy. Cns and Neurological Disorders Drug Targets 12(6): 815-829, 2014

Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatric Blood and Cancer 55(2): 344-348, 2010

The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends in Immunology 23(7): 347-351, 2002

Controversial role of smallpox on historical positive selection at the CCR5 chemokine gene (CCR5-Delta 32). Journal of Infection in Developing Countries 3(4): 324-326, 2009

The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 119(4): 551-561, 2006